Recent Thyroid Cancer News

Lower Thyroid Stimulating Hormone Levels Elevate Risk of Thyroid Cancer

(September 20, 2017)

There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published... Continue Reading

Pass it On: It’s National Thyroid Awareness Month

(September 8, 2017)

The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the neck. It produces, stores, and releases hormones that regulate vital body functions. Thyroid cancer... Continue Reading

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer

(June 6, 2017)

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up... Continue Reading

Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions

(March 3, 2017)

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common... Continue Reading

More Risk than Benefit with TSH Suppression in Thyroid Cancer without High Risk of Recurrence

(May 21, 2015)

For patients undergoing treatment for thyroid cancer who aren’t at high risk of recurrence, therapy to suppress thyrotropin (TSH) may be ineffective as well as risky. These findings were published in... Continue Reading

Target Therapy Sutent® Promising in Advanced Thyroid Cancer

(May 19, 2015)

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a... Continue Reading

Important Clues in the Development of Aggressive Thyroid Cancer

(April 16, 2015)

New insight into how anaplastic thyroid cancer (ATC) grows and spreads may provide important direction in the development of treatment. These findings were published in the Journal of Clinical Endocrinology... Continue Reading

Nexavar Approved for Metastatic Differentiated Thyroid Cancer

(December 9, 2013)

The U.S. Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) for the treatment of metastatic differentiated thyroid cancer. Differentiated thyroid cancer is the most common type of thyroid... Continue Reading

Mutations Linked to Drug Response in Medullary Thyroid Cancer

(November 15, 2013)

Metastatic medullary thyroid cancers with certain genetic mutations respond better to treatment with Cometriq™ (cabozantinib) than tumors without those mutations, according to the results of a study... Continue Reading

TSH Suppression after Thyroidectomy May Not Be Beneficial

(November 4, 2013)

Suppression of thyroid-stimulating hormone (TSH) after thyroidectomy for low-risk cancer does not appear to reduce the risk of cancer recurrence and may even increase the risk of osteoporosis in women,... Continue Reading

Next Page »